On Friday, Verve Therapeutics Inc (NASDAQ: VERV) opened lower -5.82% from the last session, before settling in for the closing price of $8.07. Price fluctuations for VERV have ranged from $7.36 to $21.42 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 126.44%. Company’s average yearly earnings per share was noted 7.64% at the time writing. With a float of $54.79 million, this company’s outstanding shares have now reached $81.97 million.
Let’s determine the extent of company efficiency that accounts for 255 employees.
Verve Therapeutics Inc (VERV) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Verve Therapeutics Inc is 30.25%, while institutional ownership is 70.27%. The most recent insider transaction that took place on Apr 02 ’24, was worth 12,475. In this transaction Chief Administrative Officer of this company sold 1,514 shares at a rate of $8.24, taking the stock ownership to the 8,659 shares. Before that another transaction happened on Nov 29 ’23, when Company’s Chief Financial Officer sold 554 for $11.45, making the entire transaction worth $6,343. This insider now owns 4,060 shares in total.
Verve Therapeutics Inc (VERV) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of 1.52 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 7.64% per share during the next fiscal year.
Verve Therapeutics Inc (NASDAQ: VERV) Trading Performance Indicators
Check out the current performance indicators for Verve Therapeutics Inc (VERV). In the past quarter, the stock posted a quick ratio of 17.24. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 50.76.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.13, a number that is poised to hit -0.71 in the next quarter and is forecasted to reach -3.10 in one year’s time.
Technical Analysis of Verve Therapeutics Inc (VERV)
Looking closely at Verve Therapeutics Inc (NASDAQ: VERV), its last 5-days average volume was 1.18 million, which is a drop from its year-to-date volume of 1.25 million. As of the previous 9 days, the stock’s Stochastic %D was 11.55%. Additionally, its Average True Range was 0.94.
During the past 100 days, Verve Therapeutics Inc’s (VERV) raw stochastic average was set at 1.97%, which indicates a significant decrease from 3.76% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 180.23% in the past 14 days, which was higher than the 99.59% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $12.66, while its 200-day Moving Average is $13.75. However, in the short run, Verve Therapeutics Inc’s stock first resistance to watch stands at $7.90. Second resistance stands at $8.20. The third major resistance level sits at $8.38. If the price goes on to break the first support level at $7.42, it is likely to go to the next support level at $7.24. Now, if the price goes above the second support level, the third support stands at $6.94.
Verve Therapeutics Inc (NASDAQ: VERV) Key Stats
There are currently 83,619K shares outstanding in the company with a market cap of 596.98 million. Presently, the company’s annual sales total 11,760 K according to its annual income of -200,070 K. Last quarter, the company’s sales amounted to 5,140 K and its income totaled -48,350 K.
